



PRESERVATION IS KEY TO AESTHETICS

Challenges to aesthetic outcomes:

Crestal Bone Loss

Average implant crestal bone loss can exceed 1.5mm during the first year of function, leading to compromised aesthetics.¹



Image courtesy of Dr. Kazuto Makigusa, Osaka, Japan.

Peri-implantitis

The prevalence of implants experiencing peri-implantitis has been reported in excess of 12%.^{2,3}






Suboptimal Outcomes

Soft-tissue recession impacts patient satisfaction.

Compromised Osseointegration

Implants lacking a complex surface topography⁴ and primary stability have been found to yield lower rates of osseointegration.⁵



Note the lack of bone-to-implant contact

- Lazzara RJ[†], Porter SS. Platform switching: A new concept in implant dentistry for controlling post restorative crestal bone levels. Int J Periodontics Restorative Dent 2006;26:9-17.
- 2. Fransson C, Lekholm U., Jemt T., Berglundh T. Prevalence of subjects with progressive bone loss at implants. Clinical Oral Implants Research 2005;16: 440-446.
- 3. Zitzmann NU. & Berglundh T. Definition and prevalence of peri-implant diseases. Journal of Clinical Periodontology 2008; 35: 286–291.
- 4. Sullivan DY, Sherwood RL, Porter SS. Long-term performance of Osseotite® Implants: A 6-year follow-up. Compendium 2001 Apr;Vol.22, No.4.
- 5. Javed F, Romanos GE. The role of primary stability for successful immediate loading of dental implants. A literature review. J Dent. 2010 Aug;38(8):612-20. Epub 2010 Jun 11.

PREVAIL®- Preservation By Design

An implant system with integrated platform switching engineered to deliver aesthetic outcomes through tissue preservation.




Connection Stability and Seal Integrity



ENHANCED OSSEOINTEGRATION

OSSEOTITE® and NanoTite™ Implant Surface Options



CRESTAL BONE PRESERVATION

Integrated Platform Switching



PRESERVATION BY DESIGN



How Preservation


Soft-Tissue Protection

Through The Certain® Internal Connection Design

45%

Higher fatigue strength²
as compared to
competitive average


Unique connection designed to provide strength and durability through deep internal engagement




50%

Higher seal strength² as compared to competitive average

Designed to reduce microleakage through exacting interface tolerances and maximized clamping forces





Gold-Tite® Surface lubricates and compresses to provide a tighter fit between implant components

113%

Increase in clamping force vs. non-coated screw⁴

Patented Gold-Tite® Screw increases clamping force to maximize abutment stability.



- 1. Competitor Reference Materials.
- Baumgarten H[†], Meltzer A[†]. Improving outcomes while employing accelerated treatment protocols within the aesthetic zone: From single tooth to full arch restorations.
 Presented at the Academy of Osseointegration, 27th Annual Meeting; March 2012; Phoenix, AZ.
- 3. Suttin Z[†], Towse R[†], Cruz J[†]. A novel method for assessing implant-abutment connection seal robustness. Poster Presentation 188: Academy Of Osseointegration, 27th Annual Meeting: 2012 March 1–3; Phoenix, Arizona.
- Byrne D, Jacobs S, O'Connell B, Houston F, Claffey N. Preloads generated with repeated tightening in three types of screws used in dental implant assemblies. J. Prosthodont. 2006 May–Jun;15(3):164-71.

Comes Together


Crestal Bone Preservation

Through Integrated Platform Switching

0.37_{mm}

Crestal bone loss

Studies have shown that implants with the PREVAIL® integrated platform switching feature demonstrated crestal bone loss as low as 0.37mm.⁵



3.4mm

4.0mm

50%

Reduction in crestal bone remodeling vs. non-platform-switched implants⁶

Medialized implantabutment junction provides support for connective tissue



Definitive restoration at the 24-month follow-up visit



Periapical radiograph taken at the 24-month follow-up visit



Periapical radiograph taken at the time of implant placement

Clinical case images courtesy of Dr. Pär-Olov Östman, Falun, Sweden.

Östman PO[†], Wennerberg A, Albrektsson T. Immediate occlusal loading of NanoTite Prevail Implants: A prospective 1-year clinical and radiographic study. Clin Implant Dent Relat Res. 2010 Mar;12(1):39–47.

^{6.} Boitel N, Andreoni C, Grunder U[†], Naef R, Meyenberg, K. A three year prospective, multicenter, randomized-controlled study evaluating platform-switching for the preservation of peri-implant bone levels. Poster presentation P83: Academy of Osseointegration, 26th Annual Meeting: 2011 March 3–5; Washington DC.



Enhanced Oss

The PREVAIL® Implant System is designed for osseointegration, peri-implantitis risk mitigation and increased primary stability.

OSSEOTITE® And NanoTite™ Surface Topography

Two well-researched surface options for bone apposition.

Osseointegration -

Surface topography targets bone apposition and early healing

NanoTite[™]: Nanoscale Topography


Discrete Crystalline Deposition (DCD) of nano-scale calcium phosphate – renders the NanoTite™ Implant a Bone Bonding®* Surface

OSSEOTITE®: Fine-Micron Topography

Dual Acid Etched 1–3 micron peak-to-peak surface for clot-to-implant attachment



*Bone Bonding® is the mechanical interlocking of the cement line matrix of bone with the implant surface.



seointegration

Peri-implantitis risk mitigation

Dual acid-etched topography at coronal aspect of the implant

Increased primary stability

Macrodesign of the implant increases Initial Bone-to-Implant Contact (IBIC)

Commercially Pure Titanium (CPTi)

Now available in OSSEOTITE® Configurations

Pre-clinical & Clinical Support

- In pre-clinical studies, the NanoTite™ DCD Surface demonstrated increased integration throughout the early healing process.¹
- Five-year study results on the OSSEOTITE® Dual Acid-Etched Surface presented no increased risk of peri-implantitis or soft tissue complications versus a hybrid surface.²
- Studies show that the macrodesign of the Tapered and Parallel Walled Implant reduces the risk of early micromotion, optimizing primary stability.^{3,4}

^{1.} Lin A, Wang CJ, Kelly J, Gubbi P[†], Nishimura I. The role of titanium implant surface modification with hydroxyapatite nanoparticles in progressive early bone-implant fixation in vivo. Int J Oral Maxillofac Implants 2009 Sep–Oct;24(5):808–816.

^{2.} Zetterqvist et al. A prospective, multicenter, randomized controlled 5-year study of hybrid and fully etched implants for the incidence of perimplantitis. J Periodontol April, 2010.

^{3.} Östman PO[↑], Wennerberg A, Ekestubbe A, et al. Immediate occlusal loading of NanoTite[™] Tapered Implants: A prospective 1-year clinical and radiographic study. Clin Implant Dent Relat Res 2012 Jan 17. [Epub ahead of print]

^{4.} Block MS⁺. Placement of implants into fresh molar sites: Results of 35 cases. J Oral Maxillofac Surg. 2011 Jan;69(1):170-4.

Ordering Information

(D) = Diameter

(P) = Platform NanoTite[™] Tapered Certain[®] PREVAIL[®] Implants

| LENGTH | 4.0mm (D) x 3.4mm (P) | 5.0mm (D) x 4.1mm (P) | 6.0mm (D) x 5.0mm (P) |
|--------|-----------------------|-----------------------|-----------------------|
| 8.5mm | NIITP4385 | NIITP5485 | NIITP6585 |
| 10.0mm | NIITP4310 | NIITP5410 | NIITP6510 |
| 11.5mm | NIITP4311 | NIITP5411 | NIITP6511 |
| 13.0mm | NIITP4313 | NIITP5413 | NIITP6513 |
| 15.0mm | NIITP4315 | NIITP5415 | NIITP6515 |

OSSEOTITE® Tapered Certain® PREVAIL® Implants

| 4.0mm (D) x 3.4mm (P) | 5.0mm (D) x 4.1mm (P) | 6.0mm (D) x 5.0mm (P) |
|-----------------------|-----------------------|-----------------------|
| XIITP4385 | XIITP5485 | XIITP6585 |
| XIITP4310 | XIITP5410 | XIITP6510 |
| XIITP4311 | XIITP5411 | XIITP6511 |
| XIITP4313 | XIITP5413 | XIITP6513 |
| XIITP4315 | XIITP5415 | XIITP6515 |

^{*} Please consult your BIOMET 3i Sales Representative for non-platform switched implant options.

NanoTite™ Certain® PREVAIL® Implants

| LENGTH | 4.0mm (D) x 3.4mm (P) | 5.0mm (D) x 4.1mm (P) |
|--------|-----------------------|-----------------------|
| 8.5mm | NIIOS4385 | NIIOS5485 |
| 10.0mm | NIIOS4310 | NIIOS5410 |
| 11.5mm | NIIOS4311 | NIIOS5411 |
| 13.0mm | NIIOS4313 | NIIOS5413 |
| 15.0mm | NIIOS4315 | NIIOS5415 |

OSSEOTITE® Certain® PREVAIL® Parallel Walled Implants

| 4.0mm (D) x 3.4mm (P) | 5.0mm (D) x 4.1mm (P) | 6.0mm (D) x 5.0mm (P) |
|-----------------------|-----------------------|-----------------------|
| XIIOS4385 | XIIOS5485 | XIIOS6585 |
| XIIOS4310 | XIIOS5410 | XIIOS6510 |
| XIIOS4311 | XIIOS5411 | XIIOS6511 |
| XIIOS4313 | XIIOS5413 | XIIOS6513 |
| XIIOS4315 | XIIOS5415 | XIIOS6515 |

^{*} Please consult your BIOMET 3i Sales Representative for non-platform switched implant options.

Tissue Preservation Meets Custom Restorative Options

NEW

Restorative **Options For The** PREVAIL® Implant





Healing Abutments



GingiHue®



PreFormance® Posts and Cylinders



Abutments



Impression Copinas



Gold-Tite® **Retaining Screws**

Including 3.4mm Restorative Options For The

Aesthetic Zone

For More Information, Please Contact Your Local BIOMET 3i Sales Representative

Aforementioned have financial relationships with BIOMET 3i LLC resulting from speaking engagements, consulting engagements and other retained services.





Global Headquarters 4555 Riverside Drive Palm Beach Gardens, FL 33410 1-800-342-5454 Outside the U.S.: +1-561-776-6700 Fax: +1-561-776-1272 www.biomet3i.com

EC REP

Europe, Middle East & Africa WTC Almeda Park, Ed. 1, Planta 1^a Pl. de la Pau, s/n 08940, Cornellà de Llobregat (Barcelona) Spain Phone: +34-93-470-55-00 Fax: +34-93-371-78-49











REV A 05/12